Share on StockTwits

Dyax Corp. (NASDAQ:DYAX) Director Thomas L. Kempner sold 37,000 shares of Dyax Corp. stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $10.39, for a total transaction of $384,430.00. Following the sale, the director now directly owns 28,041 shares in the company, valued at approximately $291,346. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Separately, analysts at Leerink Swann raised their price target on shares of Dyax Corp. from $7.00 to $8.00 in a research note on Wednesday, July 30th. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $12.14.

Shares of Dyax Corp. (NASDAQ:DYAX) traded up 0.69% during mid-day trading on Wednesday, hitting $10.20. 769,459 shares of the company’s stock traded hands. Dyax Corp. has a 1-year low of $4.13 and a 1-year high of $10.99. The stock has a 50-day moving average of $9.22 and a 200-day moving average of $8.58. The company’s market cap is $1.389 billion.

Dyax Corp. (NASDAQ:DYAX) last announced its earnings results on Tuesday, July 29th. The company reported ($0.02) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.05) by $0.03. The company had revenue of $19.59 million for the quarter, compared to the consensus estimate of $14.13 million. During the same quarter in the prior year, the company posted $0.08 earnings per share. The company’s quarterly revenue was up 72.9% on a year-over-year basis. On average, analysts predict that Dyax Corp. will post $-0.19 earnings per share for the current fiscal year.

Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.